Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Aragen Life Sciences","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clearmind Signs Development and Supply Agreement to Produce Its Drug Candidate MEAI Psychedelic Molecule With Aragen Life Sciences","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Aragen Life Sciences"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter
    ×
    FILTER:
    filter News Type
      filter Company
        filter Product Type
          filter Deal Size
            filter Upfront Payment

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Product Type

              Companies

              Aragen Life Sciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Clearmind Signs Development and Supply Agreement to Produce Its Drug Candidate MEAI Psychedelic Molecule With Aragen Life Sciences

              Details:

              In accordance with the agreement, Aragen will do a process optimization and synthesis, manufacturing and supply of MEAI to Clearmind.

              Lead Product(s): 5-Methoxy-2-Aminoindane

              Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Clearmind Medicine

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement October 26, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY